Last updated: 18 July 2019 at 4:44pm EST

Leaf Ventures Ii, L.P.New L... Net Worth




The estimated Net Worth of Leaf Ventures Ii, L.P.New L... is at least $10.9 Milione dollars as of 15 February 2013. Leaf L owns over 497,225 units of MEI Pharma Inc stock worth over $7,558,381 and over the last 12 years Leaf sold MEIP stock worth over $3,341,352.

Leaf L MEIP stock SEC Form 4 insiders trading

Leaf has made over 1 trades of the MEI Pharma Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Leaf sold 497,225 units of MEIP stock worth $3,341,352 on 15 February 2013.

The largest trade Leaf's ever made was selling 497,225 units of MEI Pharma Inc stock on 15 February 2013 worth over $3,341,352. On average, Leaf trades about 497,225 units every 0 days since 2013. As of 15 February 2013 Leaf still owns at least 2,502,775 units of MEI Pharma Inc stock.

You can see the complete history of Leaf L stock trades at the bottom of the page.



Insiders trading at MEI Pharma Inc

Over the last 12 years, insiders at MEI Pharma Inc have traded over $26,282,680 worth of MEI Pharma Inc stock and bought 597,450 units worth $2,541,200 . The most active insiders traders include Ventures Vii, Llc Vivo Vent..., Leaf Ventures Ii, L.P.New L... e Josiah T Austin. On average, MEI Pharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of $360,383. The most recent stock trade was executed by Funds Management Lp Anson A... on 22 September 2023, trading 48,060 units of MEIP stock currently worth $329,211.



What does MEI Pharma Inc do?

mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.



Complete history of Leaf L stock trades at MEI Pharma Inc

Persona
Trans.
Transazione
Prezzo totale
Leaf Ventures Ii, L.P.New L...
Vendita $3,341,352
15 Feb 2013


MEI Pharma Inc executives and stock owners

MEI Pharma Inc executives and other stock owners filed with the SEC include: